IFITM3 and small cell lung carcinoma: By integrating clinical data analysis with in vitro and in vivo experiments, we established IFITM3 as a promising biomarker for predicting the immunotherapy response in SCLC patients and proposed a novel therapeutic strategy to improve clinical outcomes.